Skip to main content

Advertisement

SpringerLink
Log in

Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

The purpose of the study is to assess the changes in the long-term effects of prostaglandin analogues (PGAs) on intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG). Data of POAG patients treated with latanoprost (0.005 %), travoprost (0.004 %), or bimatoprost (0.03 %) as the first line treatment for 5 years or more were retrospectively evaluated. Baseline ophthalmic assessment values were recorded together with the IOP at the 6th month, 1st year, and then annually. The 79 patients included 33 (41.8 %) men and 46 (58.2 %) women. There were 34 (43.0 %) patients using latanoprost (0.005 %), 23 (29.1 %) patients using bimatoprost (0.03 %), and 22 (27.8 %) patients using travoprost (0.004 %). There was no difference between the groups in terms of age, gender, or baseline IOP levels. IOP levels at the 6th month were significantly lower than baseline IOP levels in all groups (p < 0.01, Friedman test). The IOP decrease was maintained after the 6th month in all three group with no statistically significant difference compared to the 6th month IOP value (p > 0.05, Friedman test) and no statistically significant difference between the groups during follow-up (Kruskal–Wallis test, p > 0.05). IOP reductions with PGAs were adequate and stable in the 5-year follow-up period with no decrease in effectiveness over time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pizzarello L, Abiose A, Ffytche T, Duerksen R, Thulasiraj R, Taylor H, Faal H, Rao G, Kocur I, Resnikoff S (2004) VISION 2020: the right to sight: a global initiative to eliminate avoidable blindness. Arch Ophthalmol 122(4):615–620. doi:10.1001/archopht.122.4.615

    Article  PubMed  Google Scholar 

  2. Group, Collaborative Normal-Tension Glaucoma Study. (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 126(4):487–497

    Article  Google Scholar 

  3. Anderson D, Drance SM, Schulzer M (1998) The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 126(4):498–505

    Article  Google Scholar 

  4. AGIS Investigators (2000) The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130(4):429–440

    Article  Google Scholar 

  5. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson, Gordon MO (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120(6):701–713 discussion 829–730

    Article  PubMed  Google Scholar 

  6. van der Valk R, Webers CAB, Schouten JSAG, Zeegers MP, Hendrikse F, Prins MH (2005) Intraocular pressure-lowering effects of all commonly used glaucoma drugs. Ophthalmology 112(7):1177–1185. doi:10.1016/j.ophtha.2005.01.042

    Article  PubMed  Google Scholar 

  7. Kenigsberg PA (2007) Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France. Eur J Ophthalmol 17(4):521–527

    Google Scholar 

  8. Fraser SG, Wormald RPL (2006) Hospital episode statistics and changing trends in glaucoma surgery. Eye 22(1):3–7. doi:10.1038/sj.eye.6702458

    Article  PubMed  Google Scholar 

  9. Strutton DR, Walt JG (2004) Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 13(3):221–226. doi:10.1097/00061198-200406000-00008

    Article  PubMed  Google Scholar 

  10. Bean GW, Camras CB (2008) Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 53(6):S69–S84. doi:10.1016/j.survophthal.2008.08.012

    Article  PubMed  Google Scholar 

  11. Alm A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005 % latanoprost applied once daily, evening or morning. Ophthalmology 102(12):1743–1752. doi:10.1016/s0161-6420(95)30798-1

    Article  CAS  PubMed  Google Scholar 

  12. Sherwood M, Brandt J (2001) Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 45:S361–S368. doi:10.1016/s0039-6257(01)00219-3

    Article  PubMed  Google Scholar 

  13. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA, Travoprost Study G (2001) Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 132(4):472–484

    Article  Google Scholar 

  14. Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G (2007) A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin 23(3):601–608. doi:10.1185/030079907x178720

    Article  CAS  PubMed  Google Scholar 

  15. Li N, X-m Chen, Zhou Y, M-l Wei, Yao X (2006) Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Exp Ophthalmol 34(8):755–764. doi:10.1111/j.1442-9071.2006.01237.x

    Article  PubMed  Google Scholar 

  16. Holmstrom S, Buchholz P, Walt J, Wickstrom J, Aagren M (2005) Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin 21(11):1875–1883. doi:10.1185/030079905X65600

    Article  CAS  PubMed  Google Scholar 

  17. Lee CW, Buckley F, Costello S, Kelly S (2008) A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma. Curr Med Res Opin 24(8):2265–2270. doi:10.1185/03007990802273652

    Article  CAS  PubMed  Google Scholar 

  18. Kashiwagi K, Tsumura T, Tsukahara S (2008) Long-term effects of latanoprost monotherapy on intraocular pressure in Japanese glaucoma patients. J Glaucoma 17(8):662–666. doi:10.1097/IJG.0b013e318166656d

    Article  PubMed  Google Scholar 

  19. Toris CB, Gabelt BT, Kaufman PL (2008) Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 53(Suppl 1):S107–S120. doi:10.1016/j.survophthal.2008.08.010

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM (2004) Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol 49(Suppl 1):S45–S52. doi:10.1016/j.survophthal.2003.12.019

    Article  PubMed  Google Scholar 

  21. Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL, Bimatoprost Study G (2008) Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. The British journal of ophthalmology 92(10):1387–1392. doi:10.1136/bjo.2007.128454

    Article  Google Scholar 

  22. Hedman K, Watson PG, Alm A (2002) The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 47(Suppl 1):S65–S76

    Article  PubMed  Google Scholar 

  23. Watson PG, Latanoprost Study Group (1998) Latanoprost: two years’ experience of its use in the United Kingdom. Ophthalmology 105(1):82–87

    Article  Google Scholar 

  24. Agis investigators (2000) The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130(4):429–440. doi:10.1016/s0002-9394(00)00538-9

    Article  Google Scholar 

  25. Li N, Chen XM, Zhou Y, Wei ML, Yao X (2006) Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol 34(8):755–764. doi:10.1111/j.1442-9071.2006.01237.x

    Article  PubMed  Google Scholar 

  26. Parrish RK, Palmberg P, Sheu WP (2003) A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 135(5):688–703

    Article  CAS  PubMed  Google Scholar 

  27. Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G (2007) Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand 85(8):838–843. doi:10.1111/j.1600-0420.2007.00960.x

    Article  CAS  PubMed  Google Scholar 

  28. Yasemin ÜN, Tetikoğlu M, Yilmaz FSO, Öztürk M, Elçioğlu M (2011) Prostaglandin Analoglarının Etkinliği. Journal of Glaucoma, 6(4), 246-249. Glokom-Katarakt 6:246–249

    Google Scholar 

  29. Cantor LB, Hoop J, Morgan L, WuDunn D, Catoira Y (2006) Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004 % in patients with glaucoma or ocular hypertension. Br J Ophthalmol 90(11):1370–1373. doi:10.1136/bjo.2006.094326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kobelt G, Texier-Richard B, Buchholz P, Bron A, Renard JP, Rouland JF, Nordmann JP (2010) Treatment of glaucoma in clinical practice: 4-year results from a patient registry in France. J Glaucoma 19(3):199–206. doi:10.1097/IJG.0b013e3181af31d6

    Article  PubMed  Google Scholar 

  31. Hollo G, Thelen U, Teus MA, Quaranta L, Ferkova S, Babic N, Misiuk-Hojlo M, Mikropoulos DG, Kaluzny BJ, Kozobolis V, Januleviciene I, Kothy P, Camara C, Russo A, Krzyzanowska-Berkowska P, Cieslinska I, Stewart JA, Kristoffersen MS, Nelson LA, Stewart WC (2011) Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe. J Ocul Pharmacol Ther 27(5):493–498. doi:10.1089/jop.2011.0051

    Article  CAS  PubMed  Google Scholar 

  32. Uusitalo H, Pillunat LE, Ropo A, Phase III SI (2010) Efficacy and safety of tafluprost 0.0015 % versus latanoprost 0.005 % eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta ophthalmol 88(1):12–19. doi:10.1111/j.1755-3768.2010.01862.x

    Article  Google Scholar 

  33. Costagliola C, Del Prete A, Verolino M, Antinozzi P, Fusco R, Parmeggiani F, Mastropasqua L (2002) Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefe’s Arch Clin Exp Ophthalmol 240(5):379–386. doi:10.1007/s00417-002-0469-8

    Article  CAS  Google Scholar 

  34. Richter M, Krauss AH, Woodward DF, Lutjen-Drecoll E (2003) Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 44(10):4419–4426

    Article  PubMed  Google Scholar 

  35. Alm A, Widengard I (2000) Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 78(1):71–76

    Article  CAS  PubMed  Google Scholar 

  36. Riva I, Katsanos A, Floriani I, Biagioli E, Konstas AG, Centofanti M, Quaranta L (2014) Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma 23(8):535–540. doi:10.1097/IJG.0000000000000073

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Etlik Zubeyde Hanim Women’s Health Education and Research Hospital, Yeni Etlik Caddesi No: 55, Etlik, Keçiören, 06010, Ankara, Turkey

    Caner KARA

  2. Ulucanlar Eye Research and Training Hospital, Ankara, Turkey

    Emine Malkoç ŞEN, Kadriye Ufuk ELGİN & Pelin YILMAZBAŞ

  3. Department of Ophthalmology, Ankara Numune Training and Research Hospital, Ankara, Turkey

    Kurtuluş SERDAR

Authors
  1. Caner KARA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emine Malkoç ŞEN
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kadriye Ufuk ELGİN
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kurtuluş SERDAR
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pelin YILMAZBAŞ
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caner KARA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

KARA, C., ŞEN, E.M., ELGİN, K.U. et al. Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?. Int Ophthalmol 37, 619–626 (2017). https://doi.org/10.1007/s10792-016-0315-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-016-0315-3

Keywords

Search

Navigation